
- Price
- $111.26
- Day
- -0.01%
- Mkt Cap
- $192.52B
- 52W Range
- $81.97 – $137.49
- Volume
- 4.01M
- Beta
- 0.58

Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
CEO
Robert Ford
Employees
115,000
Headquarters
Abbott Park, IL, US
IPO Date
Mar 1980
Exchange
New York Stock Exchange
Phone
224 667 6100
Recent price action and historical returns
Price performance over time
1 Day
-0.02%
5 Day
+3.19%
1 Month
+24.62%
3 Months
+31.70%
6 Months
-1.27%
YTD
-11.21%
1 Year
-13.95%
3 Years
+6.01%
5 Years
-9.60%
10 Years
+151.87%
How the business makes money, by product and geography
How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A) → Operating Income → Tax / Interest → Net Income.
Five lenses on the stock. Click any card to dive deeper.
Business fundamentals
Competitive position
Model-based valuation (vs. price)
Wall Street sentiment
Smart money flows
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves

How To Invest $100,000 In A Retiree's SWAN Income Portfolio
The bull market that started in 2022 still continues, making the market somewhat overvalued, and we recommend proven strategies over investing in what is popular. A SWAN (Sleep Well At Night) income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning, especially suited for income investors and retirees. We provide a framework for a long-term portfolio with multiple buckets that is flexible to suit individual needs, limitations, and preferences.

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.

What's Backing Abbott's Established Pharmaceuticals Division Growth
ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.

Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between Aug. 12-Dec. 4 and log their donation starting Aug. 26 for a Big Ten school at BigTen.org/Abbott or by texting GIVEBLOOD to 222688 (ABBOTT) and select an exclusive, limited-edition T-shirt* while supplies last The movement aims to fuel a new generation of blood donors at a time when 2.5 million donations — nearly a quarter of all donations — come from people over the age of 65 ABBOTT PARK, Ill. and ROSEMONT, Ill.

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health.
Abbott price target lowered to $125 from $135 at UBS
Abbott price target lowered to $112 from $120 at Evercore ISI
Abbott initiated with an Outperform at Baird
Abbott price target lowered to $143 from $144 at Barclays
UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability